This research tests whether psychedelics improve adaptability in mice. After learning reward rules, mice with a single psychedelic treatment relearned new rules faster and used more information—learning not only from rewards but also from missed rewards. The findings suggest psychedelics enhance behavioral flexibility, offering clues for developing future mental health treatments.

This research explores neural remodeling—the process by which neurons form new connections after spinal cord injury. Using mouse models, the work identifies genes involved in detour pathways and enhances them through gene therapy, strengthening recovery. The goal is to develop future treatments that improve functional outcomes for people with central nervous system injuries.

This research uses a validated rodent model of psychosis to study sensory-filtering deficits linked to schizophrenia. Instead of blocking dopamine D2 receptors, the study uses CDPPB to modulate mGlu5 receptors and reduce D2 hypersensitivity. Treatment restores normal sensory gating, suggesting a promising therapeutic pathway with fewer side effects than current antipsychotics.

This research examines how combined THC and alcohol use alters neural communication and increases alcohol consumption. Using animal models, the study shows that co-use disrupts the glutamate system, heightening motivation to drink. Regulating glutamate with the compound CDPPB reduces alcohol intake, highlighting glutamate as a promising therapeutic target for addictio

This research uncovers a newly identified neural cluster that controls how much sodium animals want based on internal bodily state. By activating or inhibiting these neurons, salt perception can be shifted without changing food content. Their accessibility and immune-linked receptors offer promising targets for treating sodium overconsumption and related health disorders.

This research uncovers how two proteins, GluA1 and PKC, regulate behavioural flexibility in the striatum. Deleting GluA1 causes animals to get “stuck,” mirroring symptoms in OCD, addiction, and autism. A new molecular tool restores flexibility by 80% in hours, offering a potential pathway for future neuropsychiatric treatments.

This research focuses on developing reliable blood-based biomarkers to evaluate new treatments for hereditary frontotemporal dementia. By identifying an imbalance between two key molecules, progranulin and prosaposin, the work aims to provide accurate measures of treatment effectiveness and bring hope to families carrying this devastating genetic condition

This research maps how drugs travel from the cerebrospinal fluid into the brain, offering an alternative to the blood–brain barrier for treating Alzheimer’s disease. Using mouse models, the study identifies specific drug-entry routes and differences in drug penetration, paving the way for targeted, efficient therapies guided by a “Google Brain Map” of delivery pathways.

Migraine affects over a billion people, yet its cellular mechanisms remain unclear. This research studies how CGRP-blocking drugs interact with two key receptors—CGRP and AMY1—to understand why treatments help some patients but not others. The findings may guide development of more effective, targeted migraine therapies and reduce debilitating attacks.

Brain surgeons struggle to distinguish tumor from healthy tissue in real time, risking life-altering surgical mistakes. This research uses polarimetric imaging and machine-learning algorithms to reveal tumor borders instantly by analysing subtle differences in tissue structure. Faster, clearer, real-time imaging could revolutionise brain surgery and dramatically improve patient outcomes.